Thien Huong Huynh

Ms. Thien Huong Huynh


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2024 in Viruses
Verified
Journal Article
Open access
PDF file
TKThomas Leonidas Karadimas
Thomas Leonidas Karadimas
THThien Huong Huynh
Thien Huong Huynh
CCChloe Chose
Chloe Chose
GZGuston Zervoudakis
Guston Zervoudakis
BCBryan Clampitt
Bryan Clampitt
ALAlexander Lazarides
Alexander Lazarides
Primary bone malignancies, including osteosarcoma (OS), are rare but aggressive. Current OS treatment, involving surgical resection and chemotherapy, has improved survival for non-metastatic cases but remains ineffective for recurrent or metastatic OS. Oncolytic viral therapy (OVT) is a promising alternative, using naturally occurring or genetically modified viruses to selectively target and lyse cancer cells and induce a robust immune response against remaining OS cells. Various oncolytic viruses (OVs), such as adenovirus, herpes simplex virus, and measles virus, have demonstrated efficacy in preclinical OS models. Combining OVT with other therapeutics, such as chemotherapy or immunotherapy, may further improve outcomes. Despite these advances, challenges in reliability of preclinical models, safety, delivery, and immune response must be addressed to optimize OVT for clinical use. Future research should focus on refining delivery methods, exploring combination treatments, and clinical trials to ensure OVT’s efficacy and safety for OS. Overall, OVT represents a novel approach with the potential to drastically improve survival outcomes for patients with OS.

26 June 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
DKDavis Kuruvilla
Davis Kuruvilla
THThien Huong Huynh
Thien Huong Huynh
MNMatthew Nester
Matthew Nester
CCChloe Chose
Chloe Chose
GZGuston Zervoudakis
Guston Zervoudakis
ALAlexander Lazarides
Alexander Lazarides

18 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CCChloe Chose
Chloe Chose
TKThomas Leonidas Karadimas
Thomas Leonidas Karadimas
LHLucy Hederick
Lucy Hederick
AGAnthony Michael Griffin
Anthony Michael Griffin
VJVeena Jajoo
Veena Jajoo
ALAlexander Lazarides
Alexander Lazarides
Background/Objectives: Staged resection with temporizing vacuum-assisted closure (VAC) has been adopted to facilitate margin assessment and local control of soft tissue sarcomas (STS). Accordingly, the objective of this study is to compare rates of local recurrence (LR) among superficial STS patients treated with and without temporizing VAC therapy. Methods: We conducted a multi-institutional retrospective cohort study of superficial STS patients treated at three tertiary care centers. Patients were matched by grade, and descriptive statistics and multivariate binary logistic regression were performed. Results: After matching, 314 superficial STS patients were included in analysis. VAC patients were more likely to present with a history of prior unplanned excision (p = 0.024), with recurrent disease (p = 0.004), harbor a diagnosis of myxofibrosarcoma (p < 0.001), and have positive initial surgical margins (p < 0.001). After multivariate analysis, VAC use remained independently associated with increased LR rates (OR = 4.117; p = 0.003). Conclusions: In this multi-institutional analysis of superficial STS patients, staged resection with temporizing VAC was not associated with improved LR rates. Rather, the VAC cohort represented distinctly higher-risk tumor biology and complex oncologic presentations, in whom the risk of LR may not be fully mitigated by surgical staging alone.